NILU is WP6 leader on Regulation, Governance & Data Management, and is involved in WP2 (TRL5 Industrial Validation), WP3 (TRL6 Industrial Demonstration) and WP7 (Dissemination and exploitation). NILU, as WP leader, will also support the coordinator in scientific management (WP8 Project Coordination & Management).

The Health Effects Laboratory (HEL) has extensive experience in nanosafety, risk assessment of nanomaterials and scientific management. It gives expertise in various committees and has members in the ISO Committees for Standards Norway, appointed member in the EU Scientific Committee of Consumer Safety (SCCS) and a member of Genotoxicity Working Group in European Food Safety Authority (EFSA). Nationally, HEL has a member in the expert group for toxicology and for nanosafety research and acts also as National coordinator for nanosafety in Norway, holds workshops on nanosafety and communicates with different stakeholders and media and is coordinator of the large H2020 NMBP13 project RiskGONE for science-based risk governance for nanotechnology.

The HEL at NILU has significant infrastructure to carry out research on molecular and cellular toxicology, genetic toxicology, adverse health effects and environmental impact of nanomaterials, with significant expertise in in vitro cell culture techniques, in vivo toxicity, cytotoxicity, genotoxicity, epigenetics, mutagenicity and carcinogenicity tests, in 3D model development with focus on lung and liver models. It has large facilities including optical, fluorescence and confocal microscopy, quantitative Western blotting, quantitative fluorescent cell death analysis, and with staff with expertise in Quality Assurance, and extensive experience of establishing GLP and Standard Operation Procedures (SOPs). More recently, this infrastructure was available for use as TA (transnational access) laboratory.